Rituxan news from FierceBiotech
News
ALSO NOTED: Analysts predict trouble for second-gen Rituxan; Sucampo earns $50M on FDA approval;and much more...
> Jim Reddoch, a biotech analyst with Friedman, Billings & Ramsey, is raising some interesting questions about Genentech's second-generation Read more...
Rituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the Read more...
On a spree, Roche lands $175M deal for Piramed
Roche snapped up the UK's Piramed today in a $175 million deal that includes a $15 million milestone payment--the latest in a series of new acquisitions. Roche gets Piramed's programs involving Read more...
Cephalon, investors await FDA Treanda decision
After seeing its stock price shed about a third of its value since last summer, Cephalon is keeping its fingers crossed that tomorrow's scheduled regulatory decision on its cancer drug Treanda can Read more...
Icahn aims for Biogen control
Carl Icahn says that Biogen Idec essentially ran a sham when it put itself up for auction Read more...
ALSO NOTED: Rituxan aces RA, leukemia trials; Two die after Gardasil jab; Galapagos earns milestone; and much more...
> Roche's antibody med MabThera (Rituxan) just aced two trials aimed at expanding uses for the drug: one that pitted MabThera against rheumatoid arthritis and another that used it against adult Read more...
Genentech's blistering growth starts to cool
For several years now, Genentech has been the belle of the biotech ball. But with sales of Avastin and Read more...
Sources: Biogen gets bidders, with Pfizer in lead
The Financial Times is reporting some tantalizing details about the bidding for Biogen Idec, the biotech based in Cambridge, MA, that Read more...
What's Biogen Idec really worth to Big Pharma?
The Wall Street Journal has dug deep into the numbers at Biogen Idec, raising questions about the real value of the company. Biogen Idec is one of the original pioneers in biotechnology and recently Read more...
Positive Phase III results for Cephalon's Treanda
Cephalon is touting Phase III results of its non-Hodgkin's lymphoma drug Treanda. In the trial, 100 patients who were not responding to Genentech and Biogen Idec's Rituxan were given Treanda. The Read more...
Get more Rituxan coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends